A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR (ECREST)

• ClinicalTrials.gov Identifier: NCT02687386
• Recruitment Status: Terminated
• First Posted: February 22, 2016
• Last Update Posted: February 14, 2022
• Sponsor: Dr David Ziegler
• Collaborator: Engeneic Pty Limited
• Information provided by (Responsible Party): Dr David Ziegler, Sydney Children's Hospitals Network

Tracking Information

• First Submitted Date: January 28, 2016
• First Posted Date: February 22, 2016
• Last Update Posted Date: February 14, 2022
• Actual Study Start Date: February 8, 2016
• Actual Primary Completion Date: December 29, 2021 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: February 16, 2016)

• MTD at which fewer than one third of patients experience dose limiting toxicity as assessed by CTCAE v4.0 [ Time Frame: Day 28 (cycle 1) ]
  To determine a recommended phase 2 dose (RP2D) for EEDVsMit administered intravenously in children with recurrent / refractory solid or CNS tumours expressing EGFR
• Incidence of treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: Up to 35 days after the completion of study treatment ]
  To define and describe the toxicities of EEDVSMit administered on these schedules in children with recurrent/refractory solid or CNS tumours
• Incidence of all adverse events as assessed by CTCAE v4.0, clinically significant changes in vital signs, ECGs and clinical laboratory tests [ Time Frame: Up to 35 days after the completion of study treatment ]
  Assess the safety and tolerability of EEDVSMit in children with recurrent/refractory solid or CNS tumours.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: February 16, 2016)

• Assess disease response according to RECIST version 1.1 for children with recurrent/refractory solid or CNS tumours [ Time Frame: Up to 35 days after the completion of study treatment ]
  To preliminarily define the anti-tumour activity of EEDVSMit and assess response rates using RECIST version 1.1 criteria in children with recurrent/refractory solid or CNS tumours within the confines of a phase 1 study.
• Assess overall survival [ Time Frame: 12 months from the date the last subject was enrolled in the study. ]
  Assess overall survival (OS) in children with recurrent/refractory solid or CNS tumours treated with EEDVSMit on this schedule
• Time to response assessed by radiological imaging and RECIST v1.1 [ Time Frame: Evaluated at Day 56 (after cycle 2), then every second cycle to the end of study treatment (up to 12 months) ]
  Estimate the time to response.

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR
• Official Title: A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT (EEDVsMit) in Children With Recurrent / Refractory Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor (EGFR) (ECREST Study)
• Brief Summary: This is an open-label, sequential dose exploration study of single agent EEDVSMit administered by intravenous (IV) infusion twice weekly, followed by weekly maintenance dosing, in children with recurrent/refractory solid or CNS tumours.

Detailed Description

Eligible subjects enrolled in the study will receive EEDVSMit by IV injection twice weekly as a 20 min infusion beginning at study day 1 for the first cycle (4 weeks) then weekly for subsequent cycles. Subjects will undergo radiological assessment of their tumours after the first cycle, and every second cycle thereafter. Dosing with EEDVSmit will continue unless there is radiographic evidence of progressive disease (PD) per RECIST criteria version 1.1, the subject becomes intolerant to the study medication, signs and symptoms of clinical progression are evident as determined by the principal investigator, or the subject/parent/guardian withdraws consent. Suspected tumour progression should be confirmed with a repeat scan after 4 weeks to exclude the possibility of pseudoprogression.

Determination of EGFR expression for eligibility of subjects will be assessed at the local site. In addition, radiological assessment confirming measurable disease by the RECIST criteria is also required for entry into the Part B of the study.

The study will be conducted in two parts: Part A -Dose Exploration and Part B -Dose Expansion.

Part A - Dose Exploration:

The dose exploration part of the study is aimed at determining a recommended phase 2 dose (RP2D) in this patient group. A standard dose escalation with a rolling 6 design will be used.

Part A will commence dosing at one log scale below the maximum dose tested in the recent adult recurrent glioma trial (with the first 4 doses administered at 1/10 of the starting dose) and escalate to a maximum of 8x109 EEDVSMit evaluating the safety and tolerability, of EEDVSMit. The first 4 doses administered will be reduced by a further log reduction.

Part B - Dose expansion:

The dose expansion phase (Part B) will begin upon completion of the dose exploration (Part A). Up to 12 subjects with recurrent/refractory solid or CNS tumours will be treated at the Recommended Phase Two Dose (RPTD). All doses, including the first 4, will be at the same dose level established in Part A (RPTD).

• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Solid Tumours
• CNS Tumours

Intervention

Drug: Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)

EnGeneIC Delivery Vehicles (EDVs) are nanocells which can be loaded with anti-cancer drugs (mitoxantrone in this study) and targeted to tumor cells. These bacterially-derived nanocells are coated in bispecific antibodies (BsAb) that recognize oncogenic receptors on the tumor cell surface. Once bound to the tumour cell, the targeted and drug-loaded EDVs are endocytosed and release their toxic payload to destroy the tumor cell.

Other Name: EDV also stands for EnGeneIC Dream Vector

Study Arms

Experimental: Mitoxantrone packaged EDV

Mitoxantrone packaged EDV (EnGeneIC Dream Vector)

Intervention: Drug: Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Terminated
• Actual Enrollment (submitted: January 30, 2022): 9
• Original Estimated Enrollment (submitted: February 16, 2016): 30
• Actual Study Completion Date: December 29, 2021
• Actual Primary Completion Date: December 29, 2021 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Patients must be ≥ 2 years and ≤ 21 years old at the time of study enrolment.
• Karnofsky ≥ 50% for patients > 16 years of age and Lansky ≥ 50 for patients ≤ 16 years of age
• Patients must have relapsed or refractory solid or CNS tumours or have a diagnosis of DIPG. Patients must have had histologic verification of malignancy at original diagnosis or relapse, or a diagnosis of DIPG by MRI imaging.
• Patients must have either measurable or evaluable disease for Part B of the study only
• Patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life.
• Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study

Exclusion Criteria:

• Pregnant or breast-feeding women will not be entered on this study.
• Any active uncontrolled infection
• Patients who are known to be serologically positive for Hepatitis A, B or C, or have a history of liver disease, other forms of hepatitis or cirrhosis.
• Known positive test for human immunodeficiency virus infection
• Patients with disease of any major organ system that would compromise their ability to withstand therapy
• Concurrent or prior (within 7 days of enrolment) anticoagulation therapy, except low molecular weight heparins or low dose aspirin
• Patients receiving corticosteroids must be on a stable dose that has not been increased for at least 7 days prior to study enrolment.
• Patients who are currently receiving another investigational drug are ineligible.
• Patients who are currently receiving other antineoplastic agents are ineligible.
• All herbal supplements, vitamins, and nutritional supplements taken within the last 30 days prior to dosing on Day 1 (and continued use, if appropriate), must be reviewed and approved by the Study Chair.
• Patient will not be available for protocol-required study visits or procedures, to the best of the subject/parent/guardian's and investigator's knowledge.
• Patient has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject/parent/guardian to give written informed consent and/or to comply with all required study procedures.
• History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
• Patients will be screened for antibodies to S. typhimurium and will not be eligible until antibodies are non-detectable
• Patients will be screened for IL6 and TNFa cytokines and will not be eligible until levels are less than 3x times the detectable limit of the assay.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 2 Years to 21 Years (Child, Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Australia

Administrative Information

• NCT Number: NCT02687386
• Other Study ID Numbers: KCA001
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided

IPD Sharing Statement

• Plan to Share IPD: Undecided
• Plan Description: De-identified data is planned to be shared with EnGeneIC.

• Current Responsible Party: Dr David Ziegler, Sydney Children's Hospitals Network
• Original Responsible Party: Same as current
• Current Study Sponsor: Dr David Ziegler
• Original Study Sponsor: Same as current
• Collaborators: Engeneic Pty Limited

Investigators

• Study Chair: David Ziegler, MBBS; Sydney Children's Hospitals Network

• PRS Account: Sydney Children's Hospitals Network
• Verification Date: January 2022